Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2014
09/18/2014US20140275235 Treatment of Proliferative Disorders
09/18/2014US20140275234 Compositions and methods of using crystalline forms of wortmannin analogs
09/18/2014US20140275233 Activated soy pod fiber
09/18/2014US20140275228 Methods for treating denervation-induced muscle atrophy
09/18/2014US20140275226 Method of controlling coagulation
09/18/2014US20140275225 Modulators of pharmacological agents
09/18/2014US20140275224 Cytosine deaminase modulators for enhancement of dna transfection
09/18/2014US20140275223 MicroRNA-BASED APPROACH TO TREATING MALIGNANT PLEURAL MESOTHELIOMA
09/18/2014US20140275220 THE miRNA-212/132 FAMILY AS A THERAPEUTIC TARGET
09/18/2014US20140275217 Compositions and methods for treating cancer
09/18/2014US20140275214 Custirsen treatment with reduced toxicity
09/18/2014US20140275206 Use of levo-oxiracetam and oxiracetam in preparation of medicines for preventing or treating coma
09/18/2014US20140275204 Method of dosing and use of soft anticholinergic esters
09/18/2014US20140275202 Injectable ropinirole compositions and methods for making and using same
09/18/2014US20140275201 Identification of cancer stem cell markers and use of inhibitors thereof to treat cancer
09/18/2014US20140275200 Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
09/18/2014US20140275199 Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
09/18/2014US20140275198 Pharmaceutical composition for preventing or treating diabetes or fatty liver containing a cyp4a inhibitor as an active ingredient
09/18/2014US20140275197 Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes
09/18/2014US20140275196 Formulations of bendamustine
09/18/2014US20140275195 Stabilized pharmaceutical formulations comprising antineoplastic compounds
09/18/2014US20140275194 Films and drug delivery systems for rizatriptan
09/18/2014US20140275193 Methods for Treating Degenerative Diseases/Injuries
09/18/2014US20140275188 Use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound
09/18/2014US20140275184 Cosmetic Compositions and Methods Providing Enhanced Penetration of Skin Care Actives
09/18/2014US20140275183 Agent for reducing side effects of kinase inhibitor
09/18/2014US20140275175 Organic compounds
09/18/2014US20140275173 Oxabicyclo [2.2.2] acid gpr120 modulators
09/18/2014US20140275170 Taste masking of anesthetics and analgesics
09/18/2014US20140275169 Combination Therapies for Enhancing Protein Degradation
09/18/2014US20140275166 Spintraps and spin labels and their hydroxylamines for peri- and post-menopausal syndrome
09/18/2014US20140275164 Desethylhydroxychloroquine for the treatment of diseases associated with inflammation
09/18/2014US20140275162 Inhibition of leukotriene synthesis and activity in the treatment of sonic hedgehog-associated medulloblastoma
09/18/2014US20140275161 Combination therapy
09/18/2014US20140275160 Combination therapy
09/18/2014US20140275159 Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
09/18/2014US20140275158 Cyclohexyl isoquinolinone compounds
09/18/2014US20140275157 Method and products for enhancing cellular uptake of drug and dietary supplements
09/18/2014US20140275155 Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
09/18/2014US20140275153 Cdk9 kinase inhibitors
09/18/2014US20140275151 Dye free liquid therapeutic solution
09/18/2014US20140275150 Abuse deterrent compositions and methods of use
09/18/2014US20140275149 Abuse deterrent compositions and methods of use
09/18/2014US20140275148 Orally administrable, self-supporting dissolving film dosage forms
09/18/2014US20140275147 Compositions with a Rheological Modifier to Reduce Dissolution Variability
09/18/2014US20140275145 Compositions of a polyorthoester and an aprotic solvent
09/18/2014US20140275144 Morphine formulations
09/18/2014US20140275143 Compositions Comprising An Opioid And An Additional Active Pharmaceutical Ingredient For Rapid Onset And Extended Duration Of Analgesia That May Be Administered Without Regard To Food
09/18/2014US20140275142 Combinations of Opioid/TLR4 Antagonist and a Cyclooxygenase (COX) Inhibitor for Use in the Treatment of Pain
09/18/2014US20140275141 Combinations of Opioid/TLR4 Antagonists and Acetyl-Para-Aminophenol (APAP) for Use in the Treatment of Pain
09/18/2014US20140275140 Method and products for enhancing drug and dietary supplement bioavailability
09/18/2014US20140275139 Mdr method and products for treating hiv/aids
09/18/2014US20140275138 Method and products for treating diabetes
09/18/2014US20140275137 Tetrandrine family pharmaceutical formulations and method
09/18/2014US20140275136 Method of Treating a Proliferative Disease
09/18/2014US20140275133 Mineralocorticoid receptor antagonists
09/18/2014US20140275131 Organic compounds
09/18/2014US20140275128 Method of providing ocular neuroprotection
09/18/2014US20140275126 Processes and intermediates for preparing a medicament
09/18/2014US20140275124 Methods for treating eye disorders using dipyridamole
09/18/2014US20140275122 Voriconazole Formulations
09/18/2014US20140275119 Compounds and compositions for the treatment of parasitic diseases
09/18/2014US20140275116 Product and method for treating diarrhea
09/18/2014US20140275115 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
09/18/2014US20140275114 Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin c
09/18/2014US20140275109 Methods for Administering Aripiprazole
09/18/2014US20140275107 Cancer treatment method
09/18/2014US20140275106 Combinations of akt inhibitor compounds and vemurafenib, and methods of use
09/18/2014US20140275101 Crystalline form of 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
09/18/2014US20140275100 Pyridazine derivatives useful in therapy
09/18/2014US20140275099 Methods for treating hcv
09/18/2014US20140275098 Compositions and methods of treating pulmonary hypertension
09/18/2014US20140275094 Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis
09/18/2014US20140275089 2-Carboxamide Cycloamino Urea Derivatives in Combination with HSP90 Inhibitors for the Treatment of Proliferative Diseases
09/18/2014US20140275083 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
09/18/2014US20140275082 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
09/18/2014US20140275078 Compositions and methods for treating cancer using pi3kb inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
09/18/2014US20140275073 Methods of treating cancer sensitive to anti-egfr therapy and modifying treatment using blood biomarkers
09/18/2014US20140275072 Morpholinylbenzotriazines for use in cancer therapy
09/18/2014US20140275066 Transient Protection of Normal Cells During Chemotherapy
09/18/2014US20140275064 Dyrk1 inhibitors and uses thereof
09/18/2014US20140275060 Compounds for the treatment of neurologic disorders
09/18/2014US20140275057 Novel compounds and compositions for the inhibition of nampt
09/18/2014US20140275049 SUBSTITUTED PYRAZOLE ANALOGS As RAR ANTAGONISTS
09/18/2014US20140275046 Compositions of a polyorthoester and an aprotic solvent
09/18/2014US20140275039 Abuse deterrent compositions and methods of use
09/18/2014US20140275038 Abuse deterrent compositions and methods of use
09/18/2014US20140275036 Use and composition for treating dementia
09/18/2014US20140275027 Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
09/18/2014US20140275025 Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
09/18/2014US20140275024 Dna-pk inhibitors
09/18/2014US20140275019 Tetrahydropyridine derivatives as fabi inhibitors
09/18/2014US20140275011 Pyridine cdk9 kinase inhibitors
09/18/2014US20140275004 Pyrrolopyrimindine cdk9 kinase inhibitors
09/18/2014US20140275003 Biaryl amide compounds as kinase inhibitors
09/18/2014US20140275002 Azetidinyloxyphenylpyrrolidine compounds
09/18/2014US20140275001 Crystalline form of a beta-lactamase inhibitor
09/18/2014US20140275000 Ceftolozane pharmaceutical compositions
09/18/2014US20140274999 Cephalosporin compositions and methods of manufacture
09/18/2014US20140274998 Ceftolozane-tazobactam pharmaceutical compositions
1 ... 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 ... 7860